Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Liver Transpl. 2024 Dec 1;30(12):1226-1237. doi: 10.1097/LVT.0000000000000421. Epub 2024 Jun 12.
The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) is a standardized psychosocial assessment tool used in liver transplantation (LT) evaluation and has been primarily studied in patients with alcohol-associated liver disease. We aimed to evaluate the relationship between SIPAT score and metabolic syndrome severity and LT waitlist outcomes in a large cohort of patients with metabolic dysfunction-associated steatotic liver disease (MASLD). We performed a single-center retrospective cohort study of patients with MASLD evaluated for LT from 2014 to 2021. The utility of the previously defined total SIPAT cutoff (<21 [excellent/good candidates] vs. ≥21 [minimally acceptable/high-risk candidates]) was studied. Multivariable logistic regression analyses examined associations between continuous SIPAT scores and LT waitlisting outcomes. The Youden J statistic was used to identify the optimal SIPAT cutoff for patients with MASLD. A total of 480 patients evaluated for transplant with MASLD were included. Only 9.4% of patients had a SIPAT score ≥21. Patients with SIPAT score ≥21 had higher hemoglobin A1c compared to patients with lower psychosocial risk (median [IQR]: 7.8 [6.0-9.7] vs. 6.6 [5.8-7.9]; p = 0.04). There were no other differences in metabolic comorbidities between SIPAT groups. Increasing SIPAT score was associated with decreased odds of listing (OR: 0.82 per 5-point increase; p = 0.003) in multivariable models. A SIPAT of ≥12 was identified as the optimal cutoff in this population, resulting in an adjusted OR for a listing of 0.53 versus SIPAT <12 ( p = 0.001). In this large cohort of patients with MASLD evaluated for LT, few patients met the previously defined high SIPAT cutoff for transplant suitability. Nevertheless, increasing the SIPAT score was associated with waitlist outcomes. Our suggested SIPAT cutoff of ≥12 for patients with MASLD warrants further external validation using data from other centers.
斯坦福综合移植心理社会评估(SIPAT)是一种用于肝移植(LT)评估的标准化心理社会评估工具,主要在患有酒精相关性肝病的患者中进行研究。我们旨在评估在代谢功能障碍相关脂肪性肝病(MASLD)患者的大型队列中,SIPAT 评分与代谢综合征严重程度和 LT 候补名单结果之间的关系。我们对 2014 年至 2021 年接受 LT 评估的 MASLD 患者进行了单中心回顾性队列研究。研究了先前定义的总 SIPAT 截止值(<21[优秀/良好候选者]与≥21[最小可接受/高风险候选者])的实用性。多变量逻辑回归分析检查了连续 SIPAT 评分与 LT 候补名单结果之间的关联。Youden J 统计量用于确定 MASLD 患者的最佳 SIPAT 截止值。共纳入 480 例接受 MASLD 移植评估的患者。只有 9.4%的患者 SIPAT 评分≥21。SIPAT 评分≥21 的患者的血红蛋白 A1c 高于低心理风险的患者(中位数[IQR]:7.8[6.0-9.7]与 6.6[5.8-7.9];p=0.04)。SIPAT 组之间的其他代谢合并症无差异。多变量模型显示,SIPAT 评分增加与列入名单的几率降低相关(OR:每增加 5 分,几率降低 0.82;p=0.003)。在该人群中,SIPAT≥12 被确定为最佳截止值,导致 SIPAT<12 的调整后列入名单的几率为 0.53(p=0.001)。在接受 LT 评估的 MASLD 大型患者队列中,很少有患者符合先前为移植适宜性定义的高 SIPAT 截止值。然而,SIPAT 评分的增加与候补名单结果相关。我们建议的 MASLD 患者 SIPAT 截止值≥12 需要使用其他中心的数据进一步外部验证。